Nijmegen, Netherlands

Raymond Westheim

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 2.1

ph-index = 2

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2010-2025

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Raymond Westheim

Introduction

Raymond Westheim is a notable inventor based in Nijmegen, Netherlands. He has made significant contributions to the field of pharmaceuticals, holding a total of 4 patents. His work focuses on the development of innovative crystalline forms of various compounds, which are crucial for effective drug formulation.

Latest Patents

One of Westheim's latest patents is for the crystalline form of ozanimod hydrochloride. This invention relates to Form A of ozanimod hydrochloride, detailing processes for its preparation and pharmaceutical compositions that include this specific form. Another significant patent involves lenvatinib besylate, where he explores its crystalline forms and the processes for creating them. This patent also includes a pharmaceutical composition that comprises a therapeutically effective dose of lenvatinib besylate.

Career Highlights

Westheim is currently associated with Synthon B.V., a company known for its focus on developing complex generics and innovative medicines. His work at Synthon has allowed him to contribute to advancements in pharmaceutical sciences, particularly in the area of drug formulation.

Collaborations

Throughout his career, Westheim has collaborated with several talented individuals, including Gerrit Jan Ettema and Faysal Kalmoua. These collaborations have fostered a productive environment for innovation and have led to the successful development of new pharmaceutical products.

Conclusion

Raymond Westheim's contributions to the field of pharmaceuticals through his innovative patents highlight his expertise and dedication to improving drug formulations. His work continues to impact the industry positively, paving the way for future advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…